Centre des Médias | Bienvenue à notre salle de presse
Restez au courant des dernières nouvelles, communiqués de presse et articles connexes d’intérêt concernant GC Biotherapeutics et l’industrie des protéines plasmatiques.
CoVIg-19 PLASMA ALLIANCE BUILDS STRONG MOMENTUM THROUGH EXPANDED MEMBERSHIP AND CLINICAL TRIAL COLLABORATION
CoVIg-19 PLASMA ALLIANCE BUILDS STRONG MOMENTUM THROUGH EXPANDED MEMBERSHIP AND CLINICAL TRIAL COLLABORATION Osaka, JAPAN, and King of Prussia, PA, USA – 7 May, 2020 – The CoVIg-19 Plasma Alliance,
Clinical Immunology Society (CIS) accepts GC Mogam’s abstract for poster presentation at their national conference.
Clinical Immunology Society (CIS) accepts GC Mogam’s abstract for poster presentation at their national conference. April 2-5, 2020 The Clinical Immunology Society (CIS) educational committee approved GC Mogam’s abstract for
GC Pharma Launches Project to Develop COVID-19 Vaccine and Treatment in South Korea with support from the Korea Center for Disease Control
GC Pharma Launches Project to Develop COVID-19 Vaccine and Treatment in South Korea with support from the Korea Center for Disease Control GC Pharma announced on March 19 that it
GC Pharma marque la Journée mondiale de l’hémophilie
YONGIN, Corée du Sud, 16 avril 2019 /CNW/ – GC Pharma (anciennement Green Cross Corporation), une société biopharmaceutique sud-coréenne, se joint à la Journée mondiale de l’hémophilie, observée chaque année
Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
YONGIN, South Korea, April 3, 2019 /CNW/ — Clinigen K.K. and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280) today announced an exclusive licensing agreement in Japan to commercialize Hunterase (Idursulfase-beta) ICV,
CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome
CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome BEIJING & SHANGHAI–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat